Abstract-Atorvastatin (ATV), an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, is widely prescribed as a lipid-lowering drug. It also inhibits the RhoA-Rho-associated kinase pathway in vascular smooth muscle (SM) cells and critically inhibits SM function. Myocardin is a coactivator of serum response factor, which upregulates SM contractile proteins. The RhoA-Rho-associated kinase pathway, which directly triggers SM contraction, also increases myocardin gene expression. Therefore, we investigated whether ATV inhibits myocardin gene expression in SM cells. In mice injected with ATV (IP 20 g/g per day) for 5 days, myocardin gene expression was significantly downregulated in aortic and carotid arterial tissues with decreased expression of myocardin target genes SM ␣-actin and SM22. Correspondingly, the contractility of aortic rings in mice treated with ATV or the Rho-associated kinase inhibitor Y-27632 was reduced in response to treatment with either KCl or phenylephrine. In cultured mouse and human aortic SM cells, KCl treatment stimulated the expression of myocardin, SM ␣-actin, and SM22. These stimulatory effects were prevented by ATV treatment. ATV-induced inhibition of myocardin expression was prevented by pretreatment with either mevalonate or geranylgeranylpyrophosphate but not farnesylpyrophosphate. Treatment with Y-27632 mimicked ATV effects on the gene expression of myocardin, SM ␣-actin, and SM22, further suggesting a role for the RhoA-Rho-associated kinase pathway in ATV effects. Furthermore, ATV treatment inhibited RhoA membrane translocation and activation; these effects were prevented by pretreatment with mevalonate. We conclude that ATV inhibits myocardin gene expression in vivo and in vitro, suggesting a novel mechanism for ATV inhibition of vascular contraction. 1-3 The Ras and Rho GTPase family members are the major substrates for posttranslational modification by prenylation. 4 These small GTP-binding proteins cycle between the inactive GDP-bound state and active GTP-bound state and play critical roles in the regulation of the actin cytoskeleton and intracellular signaling pathways. It has been shown that statins regulate subcellular location 1 and activation of Ras and Rho. 5 The inhibitory effect of statins on prenylation of these small G proteins, for example, RhoA, and, therefore, the RhoA-Rho-associated kinase (ROCK) pathway, is known to contribute to protection of the cardiovascular system beyond their cholesterol-lowering effects.
T he lipid-lowering effects of 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors (statins), such as atorvastatin (ATV), have been well established in clinical patients. Statins inhibit production of isoprenoid intermediates in the cholesterol biosynthetic pathway, such as farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), to reduce posttranslational modifications of several intracellular signaling proteins, including nuclear lamins, Ras, Rho, Rac, and Rap. [1] [2] [3] The Ras and Rho GTPase family members are the major substrates for posttranslational modification by prenylation. 4 These small GTP-binding proteins cycle between the inactive GDP-bound state and active GTP-bound state and play critical roles in the regulation of the actin cytoskeleton and intracellular signaling pathways. It has been shown that statins regulate subcellular location 1 and activation of Ras and Rho. 5 The inhibitory effect of statins on prenylation of these small G proteins, for example, RhoA, and, therefore, the RhoA-Rho-associated kinase (ROCK) pathway, is known to contribute to protection of the cardiovascular system beyond their cholesterol-lowering effects. 6 It is well known that the ROCK pathway stimulates contraction through inhibition of myosin light-chain phosphatase or phosphorylation of myosin light chain 20. 7, 8 Statins attenuate spontaneous smooth muscle (SM) tone through inhibition of the RhoA-ROCK pathway, 9 suggesting an acute inhibition of SM contraction by statins. In addition, it was reported that activation of the RhoA-ROCK pathway by KCl through voltage-gated Ca 2ϩ channels upregulates the gene expression of myocardin and its target genes responsible for SM contractility in cultured vascular SM cells (SMCs). 10, 11 Myocardin, a coactivator of serum response factor, 12 is necessary and sufficient for the vascular SMC contractile phenotype. 13, 14 ATV, the most widely prescribed lipid-lowering drug, 15 was reported to inhibit the RhoA-ROCK pathway and attenuated the expression of myocardin and SM ␣-actin in human fetal penile SMCs. 16 However, it remains unknown whether ATV attenuates contractility of the blood vessel through downregulation of myocardin and its target genes. Therefore, we examined myocardin expression in vascular tissues from mice injected with ATV and their contractility in vitro. The underlying mechanisms were further investigated using cultured SMCs.
Methods
For the detailed Methods section, please see the online-only Data Supplement.
Results

Treatment With ATV Reduces Vascular Contractility
C57 mice were treated with ATV (IP 20 g/g per day) for 5 days, followed by examination of contractile responses of vascular tissues using a tissue myograph system. To compare the contractile responses of aortic rings from mice treated with and without ATV, the same lengths of rings were cut for myograph measurements. We first examined the effects of ATV treatment on contraction of mouse aortic rings induced by KCl (50 mmol/L), phenylephrine (PE; 1 mol/L), angiotensin II (1 mol/L), or prostaglandin F2␣ (1 mol/L; Figure  1A and 1B). To exclude the effect of endothelial cells, endothelium-denuded aortic rings were used for the determination of vascular contractility. Compared with contractile responses of aortic rings derived from dimethyl sulfoxide (DMSO)-treated mice, the responses of aortic rings to KCl (50 mmol/L) and PE (1 mol/L) were 47Ϯ11% and 53Ϯ10%, respectively, from ATV-treated mice ( Figure 1C ). Angiotensin II (1 mol/L)-and prostaglandin F2␣ (1 mol/ L)-induced contractions in the ATV group were even more strongly inhibited ( Figure 1C ). Injection of DMSO did not affect contractile responses compared with no injection (data not shown). In addition, in vitro treatment with low concentrations, such as 10 mol/L, of ATV did not induce significant inhibition of contractions induced by either KCl or PE in endothelium-free aortic rings derived from mice with no injection (data not shown). However, treatment with 500 mol/L of ATV for 90 minutes (but not 20 minutes) reduced contractile responses to KCl and PE ( Figure 1D ). Treatment with the ROCK inhibitor Y-27632 (10 mol/L) for 90 minutes also reduced contractile responses to KCl and PE ( Figure 1E ).
ATV Inhibits Mouse Myocardin Gene Expression In Vivo
We next evaluated the effects of ATV on the expression of myocardin protein and mRNA in hearts, aortas, and common carotid arteries (CCAs) of C57 mice with and without ATV treatment using quantitative RT-PCR ( Figure  2 ). Compared with the DMSO group or no injection control group, injection of ATV (IP 20 g/g per day) for 5 days significantly reduced myocardin gene expression in heart (to 78Ϯ9%), aorta (to 49Ϯ9%), and carotid artery (to 27Ϯ7%; Figure 2A ). Myocardin protein in heart, aorta, and carotid artery was also reduced as detected by Western blot analysis ( Figure 2B and 2C) .
ATV Inhibits the Expression of SM ␣-Actin and SM22 in Mouse Arteries
Because myocardin activity is indicated by the transcription of SM marker genes, 17 we next evaluated the effect of ATV on the expression of the SM-specific proteins SM ␣-actin and SM22 in aortas and CCAs of C57 mice with and without ATV treatment (Figure 3) . Injection of ATV (IP 20 g/g per day) for 5 days significantly reduced the expression of SM ␣-actin and SM22 proteins in aortas ( Figure 3A through 3C) and CCAs ( Figure 3D through 3F) compared with either DMSO group or no injection control group. In addition, ATV treatment reduced mRNA expression of SM ␣-actin in aorta (to 47Ϯ13%) and CCA (to 36Ϯ6%) and of SM22 in aorta (to 50Ϯ12%) and CCA (to 48Ϯ7%), when compared with the DMSO control group.
ATV Inhibits KCl-Induced Expression of Myocardin and SM-Specific Genes in Cultured Vascular SMCs, Which Is Reversed by Mevalonate and GGPP
To further study the mechanism underlying ATV-induced inhibition of myocardin expression, we cultured mouse aortic SMCs and examined ATV's effects on myocardin expression induced by KCl (60 mmol/L). It was reported previously that KCl treatment stimulates the expression of myocardin mRNA. 18 Our results showed that KCl treatment for 24 hours in the absence of serum significantly increases the expression of myocardin mRNA ( Figure 4A ) and its target genes, SM ␣-actin ( Figure 4B ) and SM22 ( Figure 4C ). ATV inhibited the upregulation of myocardin, SM ␣-actin, and SM22 evoked by KCl in a concentration-dependent manner ( Figure 4A through 4C).
Because ATV inhibits HMG-CoA reductase, we investigated whether mevalonate (Meva), GGPP, or FPP, the downstream metabolites of this enzyme, could prevent the ATVinduced inhibition of the expression of myocardin and its target genes. After starvation in medium without FBS for 24 hours, mouse aortic SMCs were treated with Meva (100 mol/L), GGPP (1 mol/L), or FPP (1 mol/L) before the addition of KCl (60 mmol/L) and ATV (10 mol/L) for 24 hours. Our quantitative RT-PCR analysis showed that Meva and GGPP but not FPP prevented the ATV-induced downregulation of myocardin mRNA expression ( Figure 4D ). As anticipated, Meva and GGPP but not FPP also significantly reduced the ATV-induced inhibition of expression of the myocardin target genes SM ␣-actin and SM22 ( Figure 4E and 4F). In addition, we performed similar studies with cultured human aortic SMCs. As shown in Figure S1A through S1C, KCl treatment also stimulated the gene expression of myocardin, SM ␣-actin, and SM22, which was reversed by Meva and GGPP.
To further extend our findings, we examined the effect of ATV on the expression of myocardin in primary cultured SMCs from porcine coronary arteries. Cultured porcine coronary artery SMCs were starved in medium without FBS for 24 hours, followed by treatment with KCl (60 mmol/L) with or without cotreatment with ATV (10 mol/L) for 24 hours. As observed in aortic SMCs from mice and humans, KCl treatment upregulated the expression of myocardin mRNA Յ3-fold over the control ( Figure S2A ). Accordingly, the expression of SM ␣-actin, one of the myocardin target genes, was significantly increased ( Figure S2B ). Consistently, pretreatment with ATV (10 mol/L) reduced the increase in mRNA expression of myocardin and SM ␣-actin induced by KCl ( Figure S2A and S2B).
Meva Treatment Prevents the Increase in RhoA Expression and the Decrease in Prenylation and Membrane Translocation of RhoA Induced by ATV
In an independent study, we examined the effects of ATV treatment on RhoA in cultured human aortic SMCs. Western blot analysis showed that ATV treatment increased RhoA protein expression, which was reduced by pretreatment with Meva ( Figure 5A ). ATV reduced the prenylation ( Figure 5B ) and membrane translocation ( Figure 5C ) of RhoA, both of which were prevented by Meva ( Figure 5B and 5C). Correspondingly, the amount of cytosolic GTP-RhoA was increased by ATV treatment with membrane-associated GTPRhoA decreased ( Figure 5D ); again this was prevented by Meva.
ROCK Inhibitor Y-27632 Inhibits KCl-Induced Expression of Myocardin and SM-Specific Genes in Cultured Human Aortic SMCs
To further reveal a role of the ROCK pathway in ATVinduced inhibition of myocardin expression, we examined the effects of the ROCK inhibitor Y-27632 on myocardin gene expression induced by KCl in human aortic SMCs. As shown in Figure 6 
Discussion
We demonstrate for the first time that ATV inhibits contractility of mouse vascular tissues, which correlates with downregulation of the expression of myocardin and its target genes, SM ␣-actin and SM22. ATV, which inhibited RhoA activation and membrane translocation, reduced the KClinduced expression of myocardin and its target genes in cultured SMCs, which was reversed by Meva and GGPP. Given the critical roles of myocardin in the regulation of the SMC contractile phenotype, our results suggest a novel mechanism whereby ATV regulates vascular functions, that is, via a nonlipid-lowering protection mechanism in the cardiovascular system.
Because of lipid-lowering effects, statins have beneficial effects in patients at high cardiovascular risk and, therefore, have become primary and secondary mechanisms for the prevention of cardiovascular diseases. Our results support a role for a nonlipid-lowering effect of statins in vascular protection. Tissue bioassays showed that ATV treatment reduced vascular contractile responses to either depolarization by KCl or vasoconstrictive factors, suggesting that ATV treatment may have a direct regulating effect on blood pressure. This hypothesis is supported by several lines of evidence. First, the expression of myocardin was downregulated by ATV. Because myocardin is a critical stimulator of SM contractile genes containing a CArG-box in their promotor regions, it is reasonable to speculate that the reduced contractility is because of downregulation of myocardin by ATV. Second, our results have directly shown that contractile and regulatory proteins SM ␣-actin and SM22 are indeed downregulated in response to ATV. This effect on SM genes could result from the decreased expression of myocardin, but it is also possible that inhibition of the RhoA-ROCK pathway by ATV has direct inhibitory effects on the expression of these SM genes. It is well known that vascular SM contraction is regulated mainly by phosphorylation and dephosphorylation of myosin regulatory light chains, 19 and activated ROCK inhibits the activity of myosin light chain phosphatase by phosphorylating its myosin-binding subunit 7 and may also directly phosphorylate myosin light chain. 8 Therefore, inhibition of the RhoA-ROCK pathway may directly inhibit SM contraction, as suggested by our observation that treatment with the ROCK inhibitor Y-27632 inhibits contraction of mouse aorta induced by KCl and PE. In addition, this hypothesis is supported by some previous studies. The ROCK pathway in blood vessels is activated in hypertensive rats, likely contributing to the development of hypertension. 20 It was reported that blood pressure is decreased by treatment with statins in adult spontaneously hypertensive rats by inhibiting the RhoA-ROCK pathway. 16, 21 Our data, therefore, suggest an additional layer of control of blood pressure by statins, that is, direct ATV-induced inhibition of myocardin expression may contribute, at least partially, to the blood pressure-lowering effects. Given that statins were reported to decrease spontaneous SM tone via the RhoA-ROCK pathway 9 and other established roles of the RhoA-ROCK pathway in the cardiovascular system, 22 it appears important for future studies to determine whether myocardin is upregulated to enhance vascular contractility in hypertension.
Our results obtained from mice have been duplicated in cultured vascular SMCs from mice, humans, and pigs. Using a cell culture model, we reproduced the report that KCl stimulates myocardin mRNA expression and the expression of its target genes through the RhoA-ROCK pathway in vascular SMCs. 11 Because ATV is well known to inhibit the RhoA-ROCK pathway in various cell types, including vascular SMCs, 23 our observation that ATV inhibits KCl- induced myocardin expression has further substantiated a novel mechanism underlying direct inhibition of vessel contractility by ATV or other statins. Finally, our results showing inhibition of RhoA activation and membrane translocation by ATV and its prevention by Meva further support the involvement of the RhoA-ROCK pathway. Our results showing that the ROCK inhibitor Y-27632 mimics the effect of ATV on the expression of myocardin, SM ␣-actin, and SM22 genes in cultured human SMCs provide additional support for this signaling mechanism.
Our current study has further established ATV inhibition of the RhoA pathway in cultured vascular SMCs (Figure 7) . ATV treatment reduced GTP-RhoA abundance and activated RhoA, resulting in accumulation of RhoA in the cytosol, which was prevented by Meva, the precursor of not only cholesterol synthesis but also various nonsteroidal isoprenoids. Because Meva is the product of HMG-CoA catalyzed by HMG-CoA reductase (Figure 7) , the reversion of ATV inhibition of myocardin gene expression by Meva confirms inhibition of HMG-CoA reductase by ATV, as described by many others. [24] [25] [26] [27] Addition of the isoprenoid GGPP but not FPP prevented ATV-induced myocardin downregulation, suggesting that geranylgeranylated proteins participate in myocardin gene expression. Because FPP is required for farnesylation of proteins such as Ras, the lack of reversing effect of FPP on ATV inhibition of myocardin gene expression suggests that protein farnesylation is not involved in ATV effects. It is known that GGPP is synthesized from both FPP and isopentenyl pyrophosphate (Figure 7 ). In the presence of ATV and inhibition of isopentenyl pyrophosphate production, the addition of exogenous FPP is not sufficient to generate GGPP for geranylgeranylation. 5, 28, 29 RhoA is one of those geranylgeranylated proteins, 5, 30 but RhoB undergoes both geranylgeranylation and farnesylation. 31, 32 Our results showing GGPP reversion of the ATV effect and its inhibition of RhoA membrane translocation and activation in human vascular SMCs, therefore, further suggest a role for RhoA in ATV-inhibited gene transcription of myocardin. This proposed mechanism is also supported by several previous studies. For example, in cultured vascular SMCs, pretreatment with ATV inhibited an angiotensin II-induced increase in GTP-bound RhoA, RhoA translocation from the cytosol to the membrane, and subsequent activation of the RhoA-ROCK pathway. 33 In addition, ATV treatment reduced the levels of activated RhoA in rat aorta in experimental models of hypertension induced by angiotensin II infusion. 33, 34 Finally, a previous report showing that expression of SM-specific genes downstream of the RhoA-ROCK cascade, such as myocardin, desmin, SM ␣-actin, and SM22, was inhibited by ATV treatment in human fetal penile SMCs 16 provides further support to our conclusions.
In addition to myocardin gene expression, the RhoA pathway is directly involved in the expression of some SM genes, such as SM ␣-actin and SM22. 16 Therefore, ATV appears to reduce the expression of proteins involved in SM contraction through multiple mechanisms with and without involvement of myocardin. However, either mechanism involves ATV inhibition of the RhoA-ROCK pathway. Taken together, our findings suggest that ATV inhibits SM contraction through downregulation of myocardin and, consequently, downregulation of the expression of its target genes.
Perspectives
In addition to their lipid-lowering effects, HMG-CoA reductase inhibitors (statins) have nonlipid-lowering effects on the cardiovascular system through the ROCK pathway. The most important finding of this study is that ATV inhibits myocardin gene expression not only in vascular but also in cardiac tissue, suggesting an additional mechanism for the beneficial effects of ATV on the cardiovascular system. Given the critical roles of myocardin in the expression of both SM and cardiac muscle genes, our findings also suggest that myocardin may become a therapeutic target in the treatment of cardiovascular disease. Porcine coronary arterial SMCs (PCASMCs) were cultured from the left descending coronary artery segments (~4 cm in length) isolated from porcine hearts of 8-month-old pigs obtained from a slaughterhouse in Tianjin, China using tissue explantation assay 4 . Cells were cultured in DMEM high glucose (4500 mg/L) medium supplemented with 20% FBS. Having reached ~90% confluence, cells were starved in medium without FBS for 24 h, followed by treatment with KCl (60 mM), with or without ATV (10 µM) for 24 h. Cells from passage 4 were used for the experiments.
Sources of Funding
RNA extraction and RT-qPCR assay -Total RNA from isolated aortae, CCAs and cultured SMCs, after various treatments, was extracted with TRIZOL according to the manufacturer's instructions. One microgram of total RNA was used for reverse transcription. One microliter of the total reverse transcription product was added to PCR mixture (20 µl) containing 10 µl 2×SYBR Green PCR master mix (Applied Biosystem, UK) and primers (sense and anti-sense; 1 µM) to determine the mRNA expression of mouse and human myocardin, SM α-actin, SM22, β-actin, and porcine myocardin, SM α-actin and β-actin. All primers were designed using IDT PrimerQuest software (Table  S1 ). The cycling conditions to amplify PCR products were: 50 °C for 2 min, 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s. The mRNA level was normalized to the β-actin mRNA level.
Detection of prenylation and membrane translocation of RhoA-To evaluate the prenylation of RhoA, Triton X-114 phase separation was conducted as previously described 5 . Equal numbers of cells from each group were used for phase separation.
Equal volumes of prenylated and unprenylated fractions were subjected to western blotting with RhoA antibody. To evaluate the membrane association of RhoA, cells were resuspended in ice-cold subcellular fractionation buffer (20 mM HEPES pH 7.4, 250 mM sucrose, 10 mM KCl, 2 mM MgCl 2 , 1 mM EGTA) plus 1 mM PMSF, 10 µM MG132, protease inhibitor cocktail, followed by sonication and passage through a 25 G needle 10 times with a 1-ml syringe. Cell debris and nuclei were excluded by centrifugation at 700 × g for 10 min. The supernatants were then centrifuged at 100,000 × g for 1 h. The supernatant was regarded as the cytosolic fraction. The pellet was resuspended in fractionation buffer containing 1% Triton X-100 and 0.02% SDS plus PMSF, MG132, and protease inhibitor cocktail. Equal amounts of protein were subjected to western blotting. To evaluate RhoA activity, GTP-bound RhoA was pulled down from equal amounts of supernatant and pellet fractions with Rhotekin RBD agarose (Millipore, Billerica, MA) according to the manufacturer's specifications and then subjected to western blotting.
Statistical analysis-Data are expressed as the mean ± SEM. The number of replicates (n) represents the number of isolated aortic ring preparations of C57BL/6 male mice in tissue myography and the number of isolated aortae and CCAs in western blot analyses. Quantification of mRNA and protein levels is expressed as percent of or fold increase over control in arbitrary densitometric units. The western blot image intensities were calculated using the Molecular Image Chemidoc XRS System (Bio-Rad Laboratories, Inc.). Densitometric signals were normalized to α-tubulin using Quantity One software (Bio-Rad Laboratories, Inc.). Differences were evaluated by Student's t-test (paired or unpaired) for comparison of two groups, and by ANOVA for comparisons involving three or more groups. P < 0.05 was considered statistically significant.
Figure S1 ATV inhibits KCl-induced expression of myocardin, SM α-actin and SM22 in human aortic SMCs, which is reversed by Meva and GGPP Human aortic SMCs were starved using medium without FBS for 24 h. Cells were then treated with 60 mM KCl in the presence of ATV (10 µM) for 24 h, followed by extraction of RNA and RT-qPCR analyses of the expression of myocardin (A), SM α-actin (B) and SM22 (C). Cultured SMCs were also pre-treated with 100 µM Meva, 1 µM GGPP or 1 µM FPP for 20 min before treatment with ATV (10 µM) and KCl (60 mM) for 24 h, followed by RT-qPCR analysis for mRNA expression of myocardin (A), SM α-actin (B) and SM22 (C). DMSO (0.02%) was the solvent control. (n = 4, * p < 0.05 versus control group, # p < 0.01 versus ATV group).
Figure S2 ATV inhibits KCl-induced expression of myocardin, SM α-actin in cultured PCASMCs
PCASMCs were starved using medium without FBS for 24 h. Cells were then treated with 60 mM KCl in the presence of ATV (10 µM) for 24 h, followed by extraction of RNA and RT-qPCR analyses of the expression of myocardin (A), SM α-actin (B). DMSO (0.02%) was the solvent control. (n = 4, * p < 0.05 versus control group, ** p < 0.01 versus control group, # p < 0.01 versus KCl group).
